Sphera Funds Management Ltd. Savara Inc Transaction History

Sphera Funds Management Ltd.

$380 Million
Q1 2025

A detailed history of Sphera Funds Management Ltd. transactions in Savara Inc stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 1,284,151 shares of SVRA stock, worth $2.74 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares

1,284,151

Previous 1,211,533 5.99%

Holding current value

$2.74 Million

Previous $3.72 Million 4.36%

% of portfolio

0.94%

Previous 0.77%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$2.32 - $3.14 $168,473 - $228,020	72,618 Added 5.99%	1,284,151 $3.56 Million
Q4 2024 Feb 14, 2025	BUY	$2.94 - $4.07 $1.91 Million - $2.64 Million	648,426 Added 115.15%	1,211,533 $3.72 Million
Q3 2024 Nov 14, 2024	SELL	$3.96 - $5.07 $1.58 Million - $2.03 Million	-399,580 Reduced 41.51%	563,107 $2.39 Million
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $3.52 Million - $5.14 Million	962,687 New	962,687 $3.88 Million
Q1 2019 May 15, 2019	SELL	$6.71 - $8.6 $738,100 - $946,000	-110,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $624,466 - $1.09 Million	-99,596 Reduced 47.52%	110,000 $833,000
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $2.2 Million - $2.7 Million	209,596 New	209,596 $2.34 Million
Q1 2018 May 10, 2018	SELL	$8.99 - $14.95 $1.8 Million - $2.99 Million	-200,000 Closed	0 $0
Q4 2017 Feb 12, 2018	SELL	$8.26 - $16.76 $2.7 Million - $5.47 Million	-326,315 Reduced 62.0%	200,000 $2.97 Million
Q3 2017 Nov 09, 2017	BUY	$5.1 - $9.55 $2.68 Million - $5.03 Million	526,315	526,315 $4.92 Million

Others Institutions Holding SVRA

# of Institutions

142

Shares Held

162M

Call Options Held

54.8K

Put Options Held

4.1K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $243M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.

Account

Sphera Funds Management Ltd. Savara Inc Transaction History